Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Aug;93(4):E96-E98.
doi: 10.1002/ajh.25035. Epub 2018 Feb 5.

A phase II study of tacrolimus and thymoglobulin as graft-versus-host-disease prophylaxis in related donor allogeneic hematopoietic cell transplantation

Dipenkumar Modi  1 , Zaid Al-Kadhimi  2 , Wei Chen  3 , Hyejeong Jang  3 , Abhinav Deol  4 , Lois Ayash  4 , Divaya Bhutani  4 , Asif Alavi  4 , Voravit Ratanatharathorn  4 , Joseph P Uberti  4
Affiliations
Clinical Trial

A phase II study of tacrolimus and thymoglobulin as graft-versus-host-disease prophylaxis in related donor allogeneic hematopoietic cell transplantation

Dipenkumar Modi et al. Am J Hematol. 2018 Aug.

Abstract

NCT01246206. The study was approved by Wayne State University Institutional Review Board.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

No relevant conflict of interests exists.

Figures

FIGURE 1
FIGURE 1
Top left: Grade II-IV aGVHDwith relapse or NRMas competing risks. Top right: Grade III-IV aGVHDwith relapse or NRMas competing risks. Middle left: cGVHDwith relapse or NRMas competing risks.Middle right: Relapse ratewith NRMas competing risk. Bottomleft:Non-relapse mortalitywith death due to relapse as competing risk. Bottom right: OS, RFS, GRFS
See this image and copyright information in PMC

References

    1. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998; 92(7):2303–2314. - PubMed
    1. Cutler C, Li S, Kim HT, et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and nonmethotrexate- containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant. 2005;11(5):383–388. - PubMed
    1. Cutler C, Kim HT, Hochberg E, et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2004;10(5):328–336. - PubMed
    1. Al-Kadhimi Z, Gul Z, Rodriguez R, et al. Anti-thymocyte globulin (thymoglobulin),tacrolimus, and sirolimus as acute graft-versus-host diseaseprophylaxis for unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(11):1734–1744. - PMC - PubMed
    1. Blaise D, Devillier R, Lecoroller-Sorriano AG, et al. Low non-relapse mortality and long-term preserved quality of life in older patients undergoing matched related donor allogeneic stem cell transplantation: a prospective multicenter phase II trial. Haematologica. 2015; 100(2):269–274. - PMC - PubMed

LinkOut - more resources